Teva Pharma (TEVA) Issues Positive Update from Reslizumab Phase III
Tweet Send to a Friend
Teva Pharma (NYSE: TEVA) announced positive new data from Phase III studies of the company’s anti-IL5 monoclonal antibody, reslizumab, in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
